The foundation for stroke prevention in current clinical practice

DOI: https://doi.org/10.29296/25877305-2018-07-01
Download full text PDF
Issue: 
7
Year: 
2018

V. Shishkova(1), Candidate of Medical Sciences; Professor T. Adasheva(2), MD; L. Kapustina(3) 1-Center for Speech Pathology and Neurorehabilitation, Moscow 2-A.I. Evdokimov Moscow State University of Medicine and Dentistry 3-City Polyclinic Sixty-Nine, Moscow Healthcare Department

Ischemic stroke (IS) is a complex multifactorial disease with a now widely discussed polyfactor hereditary component and biochemical, metabolic, inflammatory, coagulation, and hemodynamic factors. Its development is also influenced by environmental conditions. The assessment of the contribution of various risk factors to the prognosis of a first and recurrent IS can serve as the basis for developing personalized programs for primary and secondary IS prevention, especially in high-risk group patients. The issues of primary and secondary stroke prevention are common for neurologists, cardiologists, endocrinologists, therapists, and, of course, general practitioners.
Keywords: 
neurology
ischemic stroke
genetics of ischemic stroke
stroke predictors
prognostic model

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Insul't. Rukovodstvo dlja vrachej. Pod red. S.V. Kotova, L.V. Stahovskoj / M.: Izdatel'stvo MIA, 2013.
  2. O’Donnell M., Xavier D., Liu L. et al. INTERSTROKE Investigators. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study // Lancet. – 2010; 376: 112–23. https://doi.org/10.1016/S0140-6736(10)60834-3
  3. Christiansen C., Gerds T., Olesen J. et al. Atrial fibrillation and risk of stroke: a nationwide cohort study // Europace. – 2016; 18: 1689–97. https://doi.org/10.1093/europace/euv401
  4. Avdonina M.A., Nasedkina T.V., Ikonnikova A.Ju. i dr. Issledovanie assotsiatsii polimorfnyh markerov genov F12, PON1, PON2, NOS2, PDE4D, HIFla, GPIba, CYP11B2 s ishemicheskim insul'tom sredi russkogo naselenija Tsentral'noj Rossii // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2012; 112 (2): 51–4.
  5. Shishkova V.N., Remennik A.Ju., Valjaeva V.N. i dr. Izuchenie assotsiatsij polimorfnyh variantov genov lipidnogo i uglevodnogo obmenov, sosudistogo vospalenija i nejrotransmitternyh sistem s razvitiem pervogo ishemicheskogo insul'ta // Kardiovask. ter. i profilakt. – 2017; 16 (5): 27–33. https://doi.org/10.15829/1728-8800-2017-5-27-33
  6. Shishkova V.N. Adasheva T.V, Remennik A.Ju. i dr. Prognosticheskaja znachimost' kliniko-antropometricheskih, biohimicheskih, metabolicheskih, sosudisto-vospalitel'nyh i molekuljarno-geneticheskih markerov v razvitii pervogo ishemicheskogo insul'ta // Zhurn. nevrol. i psihiat. – 2018; 2: 4–11.
  7. Shishkova V.N., Adasheva T.V., Remennik A.Ju. i dr. Prediktory razvitija povtornogo ishemicheskogo insul'ta // Vrach. – 2018; 29 (2): 38–44. DOI: 10.29296/25877305-2018-02-10
  8. Fonjakin A.V., Geraskina L.A.. Profilaktika ishemicheskogo insul'ta. Rekomendatsii po antitromboticheskoj terapii. Pod red. Z.A. Suslinoj / M.: Ima-Press, 2014.
  9. Furie K., Kasner S., Adams R. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline // Stroke. – 2011; 42: 227–76.
  10. Goldstein L., Bushnell Ch., Adams R. et al. Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association // Stroke. – 2011; 42: 517–84.
  11. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack / The European Stroke Organization (ESO), 2008; 120 p. http://www.eso-stroke.org
  12. Jauch E., Saver J., Adams H. et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke // Stroke. – 2013; 44: 870–947.
  13. Kernan W. et. al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association / American Stroke Association // Stroke. – 2014; 45: 2160–236.
  14. Intercollegiate Stroke Working Party. National clinical guideline for stroke, 4th ed. / London: Royal College of Physicians, 2012.
  15. Rashid P., Leonardi-Bee J., Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review // Stroke. – 2003; 34 (11): 2741–8.
  16. Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noj gipertenzii» Rossijskogo meditsinskogo obschestva po arterial'noj gipertonii, 2013.
  17. Korzun A.I., Kirillova M.V. Sravnitel'naja harakteristika ingibitorov APF / SPb: VMedA, 2003; 24 s.
  18. Chukanova E.I. Sovremennye aspekty epidemiologii i lechenija hronicheskoj ishemii mozga na fone arterial'noj gipertenzii (rezul'taty programmy KALIPSO) // Nevrologija, nejropsihiatrija, psihosomatika. – 2011; 3 (1): 38–42.
  19. Putilina M.V., Baranova O.A. Rezul'taty mnogotsentrovoj kliniko-epidemiologicheskoj nabljudatel'noj programmy «GLOBUS» // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2014; 5: 33–8.
  20. Evdokimova A.G. i dr. Klinicheskaja effektivnost' kombinirovannoj antigipertenzivnoj terapii v fiksirovannyh dozah: fokus na Gipotef // Terapija. – 2016; 6 (10): 68–78.
  21. Skotnikov A.S., Hamurzova M.A. Organoprotektivnye svojstva gipotenzivnoj terapii kak profilaktika razvitija «sosudistoj» komorbidnosti // Lechaschij vrach. – 2017; 7: 16–24.
  22. Skotnikov A.S., Judina D.Ju., Stahnev E.Ju. Gipotenzivnaja terapija komorbidnogo bol'nogo: na chto orientirovat'sja v vybore lekarstvennogo sredstva // Lechaschij vrach. – 2018; 2: 24–30.
  23. Skotnikov A.S., Hamurzova M.A. Novye kombinatsii dlja kompleksnogo lechenija arterial'noj gipertenzii v pomosch' vrachu obschej praktiki // Poliklinika. Kardiolog segodnja. Spetsvypusk. – 2017/2018; 1: 47–55.
  24. Rekomendatsii EOK/EOA po diagnostike i lecheniju dislipidemij 2016 // Ros. kardiol. zhurn. – 2017; 5 (145): 7–77.
  25. International Diabetes Federation, Diabetes Atlas, 5th ed. International Diabetes Federation, 2011.
  26. Dedov I.I., Shestakova M.V. Saharnyj diabet / M: Meditsinskoe Informatsionnoe Agenstvo, 2005; 677 s.
  27. Stamler J., Vaccaro O., Neaton J. et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care. – 1993; 16 (2): 434–44.
  28. Shishkova V.N. Vzaimosvjaz' razvitija metabolicheskih i kognitivnyh narushenij u patsientov s saharnym diabetom, prediabetom i metabolicheskim sindromom // Consilium Medicum (Nevrologija/revmatologija). – 2010; 1: 36–43.
  29. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in atrial fibrillation: a systematic review // Neurology. – 2007; 69 (6): 546–54.
  30. Camm A., Lip G., de Caterina R. et al. 2012 focused up date of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation // Eur. Heart J. – 2012; 33: 2719–47.
  31. Diagnostika i lechenie fibrilljatsij predserdij. Rekomendatsii RKO, VNOA i ASSH, 2017.
  32. Cannon Ch., Bhatt D., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation // N. Engl. J. Med. – 2017; 377: 1513–24.
  33. Steffel J. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation // Eur. Heart J. – 2018; 39 (16): 1330–93. DOI: 10.1093/eurheartj/ehy136
  34. Skotnikov A.S. i dr. Sravnenie vlijanija na agregatsiju trombotsitov original'nogo preparata (Plaviks) i ego dzhenerika (Klapitaks): Rezul'taty nabljudatel'nogo issledovanija // Ros. kardiol. zhurn. – 2018; 4 (156): 75–81. http://dx.doi.org/10.15829/1560-4071-2018-4-75-81